Is there an association between treatment with retinoids and sexual dysfunction?
Authors of a study published in the British Journal of Dermatology assessed data regarding sexual dysfunction association with the use of retinoids. A total of 11 studies were included, with three studies reporting on etretinate, two on acitretin, and six on isotretinoin. More than 300 cases of post-retinoid sexual dysfunction were reported across the studies. Vulvovaginal dryness, dyspareunia, vaginal bleeding, and loss of libido were the most common effects reported by females. There was conflicting data across studies regarding the risk of erectile dysfunction in males treated with isotretinoin. Further studies are warranted to determine whether there is a true association, the authors noted.
DermWorld Insights and Inquiries: Topical isotretinoin for ichthyoses: Striving for an ‘A’ grade
Two meaningful events changed my life in 1982 — my marriage and the introduction of isotretinoin. Forty-two years later, both remain front and center. As most ichthyoses are genodermatoses, the future lies in therapies that target specific mutations rather than those that rely on broad pharmacologic strokes of retinoids. Inevitably, retinoid use — oral or topical — in patients with ichthyoses will become passé. For now, their utilization is the standard of care. Attending the focus session, “Think like an expert about ichthyosis” at the Annual Meeting in San Diego rejuvenated my enthusiasm for isotretinoin when I learned of a new topical formulation that is reportedly safe and effective. Keep reading!
FDA approves rosacea treatment
The FDA has approved minocycline hydrochloride (Emrosi) for the treatment of inflammatory rosacea in adults. In two phrase 3 clinical trials, the treatment showed significant superiority over both the current standard-of-care treatment (doxycycline) and placebo as well as a reduction in total inflammatory lesion count. The extended-release 40 mg capsules are expected to be available in the first or second quarter of 2025.
Efficacy of intralesional vitamin D3 vs. triamcinolone in patients with keloids
A study published in Wound Repair and Regeneration assessed the efficacy and safety of treatment with intralesional vitamin D3 versus triamcinolone in patients with keloids. Overall, four injections were administered at four-week intervals with an eight-week follow-up period. Treatment with triamcinolone resulted in significantly better improvement compared with treatment with vitamin D3 but was associated with a higher rate of side effects, such as hypopigmentation and atrophy.
Predictive factors for long-term high response to upadacitinib in patients with AD
Authors of a retrospective study published in Dermatitis examined the predictive factors for long-term high response to upadacitinib 15 mg or 30 mg. Patients who had a long-term high response to 15-mg upadacitinib showed a lower baseline Eczema Area and Severity Index (EASI) of the head and neck, IgE level, systemic inflammatory response index, and rate of bronchial asthma than those who had a low response. Patients who had a long-term high response to 30-mg upadacitinib showed lower baseline IgE levels than those who had a low response.
Patients with lower baseline EASI of head and neck, IgE, or systemic inflammatory response index or without bronchial asthma and those with lower baseline IgE may have a higher potential to become long-term high responders to upadacitinib 15 mg and 30 mg treatment, respectively, the authors concluded.
Dermatologists discuss the influx of new JAK inhibitors in dermatology and how they are breaking new ground for the specialty. Read more.
The American Academy of Dermatology is a non-profit professional organization and does not endorse companies or products. Advertising helps support our mission.
